Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Comment by MirrorWorldManon Jan 24, 2021 8:27pm
135 Views
Post# 32372360

RE:RE:RE:RE:RE:RE:RE:Top 5 10x for 2021

RE:RE:RE:RE:RE:RE:RE:Top 5 10x for 2021How many times do I need to answer the stupid "why am I here?" question. 
For the last time (hopefuly) , I am betting on the partner to do something with what we got, not Sirona's managment team. Howie has repeatedly demonstrated his inablitiy to be quarter back.  So many fumbles it is ridiculous.   
This is a  risk sunken cost company, with residual value in their partnerships. Although not as high as everyone seems to believe.  Just look at so many other BioTechs with partners, the vast majority never achieve the hopefull value their long term holders expect.  Anyway the value is Not in Howie. So many years of nothing but rhetoric.   The CEO is very very critical in Biotechs value and he is one of the least performing I have ever seen.   He would of been fired from almost every ther BoD's I can immagine.   Other worse ones I have witnessed have diluted value out of existence.   So he not quite at the worst stage. 
 On an opportunistic tone, once the picture becomes less blurry.   it may be worth transferring a chunk of assests out of here into whoever picks up our molecules.   I invest in Molecules and People.  Unfortunately I have given up on the people side in this company.
Ask yourself why you continually talk yourself into the what if.\s, and just waits, and maybe's,  those dont pay out.
<< Previous
Bullboard Posts
Next >>